

Kyowa Hakko Kirin Co., Ltd.

Appendix to the Consolidated Financial Summary Fiscal 2016 First Quarter

(January 1, 2016 - March 31, 2016)

- This document was made as a supplement to the Kessan Tanshin (financial report), disclosed at the Tokyo Stock Exchange on April 27, 2016 for the first quarter of Fiscal 2016, the three-month period from January 1, 2016 to March 31, 2016.
- This document contains forward-looking statements based on a number of assumptions and beliefs held by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.
- Figures presented in this document have been rounded down to the nearest whole number.

Index	Page
I. Consolidated Financial Results	
1.Trends in consolidated income	1
2.Trends in results by segment	2
3.Other trends	3
II. Consolidated Balance Sheets	4
III. Operating Income or Loss by Segment	
1.Pharmaceuticals segment	5
2.Bio-Chemicals segment	5
IV. Operating Income or Loss of Main Pharmaceuticals Subsidiaries	6
V. Kyowa Hakko Kirin Sales of Main Products	7
VI. R&D Pipeline	9

The average exchange rate for each period was as follows:

Unit: yen

	2015 results				2016 results				2016 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
USD	119	120	120	121	117	-	-	-	119	119
EURO	138	135	135	135	128	-	-	-	137	137
GBP	183	183	186	185	169	-	-	-	187	187

Contact
 Kyowa Hakko Kirin Co., Ltd.
 Corporate Communications Department
 Tel 81 3 3282 0009

I. Consolidated Financial Results

1. Trends in consolidated income

Accumulative

Billions of yen, rounded down

	FY 2015 results				FY 2016 results								FY 2016 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	%	Jan - June	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	89.5	178.8	272.9	364.3	88.4	(1.1)	99%	-	-	-	-	-	-	171.0	96%	351.0	96%
Gross Profit	51.9	108.8	170.4	225.3	51.7	(0.1)	100%	-	-	-	-	-	-	101.6	93%	216.2	96%
Selling, general and administrative expenses	42.5	86.3	129.5	181.6	43.2	0.6	101%	-	-	-	-	-	-	92.6	107%	186.2	103%
Operating income	9.3	22.4	40.8	43.7	8.5	(0.8)	91%	-	-	-	-	-	-	9.0	40%	30.0	69%
Non-operating income	1.1	1.8	2.7	2.9	0.9	(0.1)	84%	-	-	-	-	-	-	-	-	-	-
Non-operating expenses	2.4	4.2	6.9	7.4	1.6	(0.7)	68%	-	-	-	-	-	-	-	-	-	-
Ordinary income	8.0	20.0	36.6	39.2	7.8	(0.2)	97%	-	-	-	-	-	-	-	-	25.0	64%
Extraordinary income	0.6	0.6	7.5	8.1	4.3	3.6	696%	-	-	-	-	-	-	-	-	-	-
Extraordinary loss	0.4	3.4	3.5	5.9	-	(0.4)	-	-	-	-	-	-	-	-	-	-	-
Profit before income taxes	8.2	17.2	40.6	41.4	12.1	3.8	147%	-	-	-	-	-	-	-	-	26.0	63%
Income taxes	3.6	7.6	14.6	11.6	4.7	1.0	129%	-	-	-	-	-	-	-	-	-	-
Profit	4.6	9.5	26.0	29.7	7.3	2.7	161%	-	-	-	-	-	-	-	-	16.0	54%
Amortization of goodwill	3.3	6.6	10.0	13.4	3.2	(0.0)	98%	-	-	-	-	-	-	-	-	13.4	-
Share of profit/loss of entities accounted for using equity method	(1.1)	(2.2)	(3.6)	(3.7)	(1.0)	0.0	-	-	-	-	-	-	-	-	-	(4.4)	-
Core operating income*	11.5	26.8	47.3	53.4	10.7	(0.8)	93%	-	-	-	-	-	-	-	-	39.0	73%
EPS prior to amortization of goodwill (¥/share)	14.53	29.63	66.03	78.95	19.49	4.96	134%	-	-	-	-	-	-	-	-	53.87	68%
ROE prior to amortization of goodwill (%)	-	-	-	7.1	-	-	-	-	-	-	-	-	-	-	-	-	-

* Core operating income = Operating income + Amortization of goodwill + Share of profit/loss of entities accounted for using equity method

Note: No revisions have been made to the consolidated results forecasts released on January 29, 2016.

Quarterly

Billions of yen, rounded down

	FY 2015 results				FY 2016 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change Amount	%	Apr - Jun	%	Jul - Sep	%	Oct - Dec	%
Net sales	89.5	89.2	94.1	91.3	88.4	(1.1)	99%	-	-	-	-	-	-
Gross Profit	51.9	56.9	61.5	54.9	51.7	(0.1)	100%	-	-	-	-	-	-
Selling, general and administrative expenses	42.5	43.8	43.1	52.0	43.2	0.6	101%	-	-	-	-	-	-
Operating income	9.3	13.1	18.4	2.8	8.5	(0.8)	91%	-	-	-	-	-	-
Non-operating income	1.1	0.7	0.9	0.1	0.9	(0.1)	84%	-	-	-	-	-	-
Non-operating expenses	2.4	1.8	2.7	0.5	1.6	(0.7)	68%	-	-	-	-	-	-
Ordinary income	8.0	11.9	16.6	2.5	7.8	(0.2)	97%	-	-	-	-	-	-
Extraordinary income	0.6	-	6.9	0.6	4.3	3.6	696%	-	-	-	-	-	-
Extraordinary loss	0.4	3.0	0.0	2.4	-	(0.4)	-	-	-	-	-	-	-
Profit before income taxes and minority interests	8.2	8.9	23.4	0.7	12.1	3.8	147%	-	-	-	-	-	-
Income taxes	3.6	4.0	6.9	(3.0)	4.7	1.0	129%	-	-	-	-	-	-
Profit	4.6	4.9	16.5	3.7	7.3	2.7	161%	-	-	-	-	-	-
Amortization of goodwill	3.3	3.3	3.3	3.3	3.2	(0.0)	98%	-	-	-	-	-	-
Share of profit/loss of entities accounted for using equity method	(1.1)	(1.1)	(1.3)	(0.1)	(1.0)	0.0	-	-	-	-	-	-	-
Core operating income	11.5	15.3	20.4	6.0	10.7	(0.8)	93%	-	-	-	-	-	-

I. Consolidated Financial Results

2. Trends in results by segment

(1) Reported segment

Accumulative

Billions of yen, rounded down

	FY 2015 results				FY 2016 results								FY 2016 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	89.5	178.8	272.9	364.3	88.4	(1.1)	99%	-	-	-	-	-	-	171.0	96%	351.0	96%
Pharmaceuticals	68.0	135.3	208.7	279.2	68.0	(0.0)	100%	-	-	-	-	-	-	129.0	95%	268.0	96%
Elimination of inter-segment sales	(0.2)	(0.4)	(0.6)	(0.8)	(0.2)	0.0	-	-	-	-	-	-	-	-	-	(1.0)	-
Bio-Chemicals	22.1	45.0	67.1	88.8	21.2	(0.9)	96%	-	-	-	-	-	-	43.0	96%	87.0	98%
Elimination of inter-segment sales	(0.3)	(1.0)	(2.2)	(2.9)	(0.5)	(0.1)	-	-	-	-	-	-	-	(1.0)	-	(3.0)	-
Operating income	9.3	22.4	40.8	43.7	8.5	(0.8)	91%	-	-	-	-	-	-	9.0	40%	30.0	69%
Pharmaceuticals	7.7	18.5	34.9	36.2	5.9	(1.8)	76%	-	-	-	-	-	-	5.2	28%	23.0	64%
Bio-Chemicals	1.4	3.9	6.4	8.1	2.3	0.8	159%	-	-	-	-	-	-	3.8	95%	7.0	86%
Eliminations	0.0	(0.0)	(0.5)	(0.5)	0.3	0.2	325%	-	-	-	-	-	-	-	-	-	-
Core operating income	11.5	26.8	47.3	53.4	10.7	(0.8)	93%	-	-	-	-	-	-	-	-	39.0	73%
Pharmaceuticals	9.8	22.6	40.9	45.2	7.9	(1.8)	81%	-	-	-	-	-	-	-	-	31.3	69%
Bio-Chemicals	1.6	4.3	6.9	8.7	2.4	0.8	153%	-	-	-	-	-	-	-	-	7.6	87%
Eliminations	0.0	(0.0)	(0.5)	(0.5)	0.3	0.2	325%	-	-	-	-	-	-	-	-	-	-

Quarterly

Billions of yen, rounded down

	FY 2015 results				FY 2016 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change Amount	%	Apr - Jun	%	Jul - Sep	%	Oct - Dec	%
Net sales	89.5	89.2	94.1	91.3	88.4	(1.1)	99%	-	-	-	-	-	-
Pharmaceuticals	68.0	67.2	73.4	70.5	68.0	(0.0)	100%	-	-	-	-	-	-
Elimination of inter-segment sales	(0.2)	(0.2)	(0.2)	(0.2)	(0.2)	0.0	-	-	-	-	-	-	-
Bio-Chemicals	22.1	22.8	22.0	21.7	21.2	(0.9)	96%	-	-	-	-	-	-
Elimination of inter-segment sales	(0.3)	(0.7)	(1.1)	(0.6)	(0.5)	(0.1)	-	-	-	-	-	-	-
Operating income	9.3	13.1	18.4	2.8	8.5	(0.8)	91%	-	-	-	-	-	-
Pharmaceuticals	7.7	10.7	16.3	1.2	5.9	(1.8)	76%	-	-	-	-	-	-
Bio-Chemicals	1.4	2.5	2.4	1.6	2.3	0.8	159%	-	-	-	-	-	-
Eliminations	0.0	(0.1)	(0.4)	(0.0)	0.3	0.2	325%	-	-	-	-	-	-
Core operating income	11.5	15.3	20.4	6.0	10.7	(0.8)	93%	-	-	-	-	-	-
Pharmaceuticals	9.8	12.8	18.3	4.2	7.9	(1.8)	81%	-	-	-	-	-	-
Bio-Chemicals	1.6	2.6	2.5	1.8	2.4	0.8	153%	-	-	-	-	-	-
Eliminations	0.0	(0.1)	(0.4)	(0.0)	0.3	0.2	325%	-	-	-	-	-	-

(2) Regional sales

Billions of yen, rounded down

	FY 2015 results				FY 2016 results								FY 2016 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Percentage of consolidated sales	Jan - Mar	Percentage of consolidated sales	Jan - Jun	Percentage of consolidated sales	Jan - Sep	Percentage of consolidated sales	Jan - Dec	Percentage of consolidated sales	Jan - Jun	Percentage of consolidated sales	Jan - Dec	Percentage of consolidated sales
Japan	61.6	122.8	184.4	249.9	68.6%	63.1	71.4%	-	-	-	-	-	-	116.6	68.2%	240.2	68.4%
International	27.9	56.0	88.4	114.3	31.4%	25.2	28.6%	-	-	-	-	-	-	54.3	31.8%	110.7	31.6%
Americas	7.4	13.7	19.5	24.1	6.6%	5.9	6.7%	-	-	-	-	-	-	10.3	6.0%	23.0	6.6%
Europe	13.2	26.3	45.5	57.9	15.9%	12.2	13.9%	-	-	-	-	-	-	28.2	16.5%	55.3	15.8%
Asia	7.0	15.4	22.6	31.0	8.5%	6.8	7.8%	-	-	-	-	-	-	15.2	8.9%	31.5	9.0%
Others	0.2	0.4	0.6	1.0	0.3%	0.1	0.2%	-	-	-	-	-	-	0.4	0.2%	0.8	0.2%
Total consolidated net sales	89.5	178.8	272.9	364.3	100%	88.4	100%	-	-	-	-	-	-	171.0	100%	351.0	100%

* Sales classified by region or country based on location of customer.

I. Consolidated Financial Results
3. Other trends
(1) R&D Expenses
Billions of yen, rounded down

	FY 2015 results				FY 2016 results				FY 2016 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
R&D expenses	12.1	24.1	36.2	51.6	13.7	-	-	-	28.9	56.1
<i>R&D to net sales ratio</i>	13.5%	13.5%	13.3%	14.2%	15.5%	-	-	-	17.0%	16.0%
Pharmaceuticals	11.3	22.5	33.8	48.3	12.9	-	-	-	27.1	52.6
<i>R&D to net sales ratio</i>	16.7%	16.7%	16.2%	17.3%	19.1%	-	-	-	21.1%	19.6%
Bio-Chemicals	0.7	1.6	2.3	3.2	0.7	-	-	-	1.7	3.5

(2) Capital Expenditure (Property, plant and equipment)
Billions of yen, rounded down

	FY 2015 results				FY 2016 results				FY 2016 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
Capital expenditure	5.6	10.2	13.3	19.0	3.9	-	-	-	11.1	27.7
Pharmaceuticals	2.2	4.6	6.9	10.5	2.6	-	-	-	7.2	16.0
Bio-Chemicals	3.3	5.6	6.3	8.4	1.2	-	-	-	3.9	11.6

(3) Depreciation Expenses (Property, plant and equipment and Intangible assets)
Billions of yen, rounded down

	FY 2015 results				FY 2016 results				FY 2016 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
Depreciation and amortization expenses	5.5	11.2	17.1	23.1	5.7	-	-	-	12.0	24.4
<i>Amortization of intangible assets</i>	2.6	5.1	7.7	10.2	2.4	-	-	-	4.9	9.8
Pharmaceuticals	4.0	8.1	12.3	16.5	4.0	-	-	-	8.5	17.5
<i>Amortization of intangible assets</i>	2.6	5.1	7.6	10.2	2.3	-	-	-	4.9	9.8
Bio-Chemicals	1.4	3.0	4.8	6.5	1.7	-	-	-	3.4	6.9

*Depreciation expenses for intangible assets do not include amortization of goodwill.

(4) Amortization of Goodwill
Billions of yen, rounded down

	FY 2015 results				FY 2016 results				FY 2016 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Jun	Jan - Dec
Amortization expenses	3.3	6.6	10.0	13.4	3.2	-	-	-	6.7	13.4
Pharmaceuticals	3.1	6.3	9.6	12.8	3.1	-	-	-	6.4	12.8
Bio-Chemicals	0.1	0.3	0.4	0.6	0.1	-	-	-	0.3	0.6

II. Consolidated Balance Sheets

Billions of yen, rounded down

	2014	2015				2016				
	Dec 31	Mar 31	Jun 30	Sep 30	Dec 31	Mar 31	Change previous year end	Jun 30	Sep 30	Dec 31
Assets	719.1	699.8	708.5	708.2	720.7	702.5	(18.1)	-	-	-
Current assets	283.1	270.3	278.0	307.4	324.4	310.3	(14.1)	-	-	-
Cash and deposits	20.6	16.5	16.2	17.2	13.2	13.2	0.0	-	-	-
Notes and accounts receivable-trade	108.8	106.2	105.2	100.7	106.8	106.9	0.1	-	-	-
Inventories	91.2	91.5	90.2	88.1	84.8	83.4	(1.3)	-	-	-
Deferred tax assets	10.6	10.2	10.2	9.8	11.1	10.7	(0.3)	-	-	-
Short-term loans receivable	41.6	36.2	45.1	80.0	96.1	87.3	(8.8)	-	-	-
Accounts receivable - other	5.3	5.4	5.6	6.2	7.6	4.3	(3.3)	-	-	-
Other	4.7	3.9	5.1	5.1	4.6	4.2	(0.3)	-	-	-
Non-current assets	435.9	429.5	430.5	400.7	396.3	392.2	(4.0)	-	-	-
Property, plant and equipment	151.8	154.5	152.9	149.8	147.0	145.8	(1.1)	-	-	-
Buildings and structures	44.4	45.5	48.2	49.0	49.4	48.6	(0.8)	-	-	-
Machinery, equipment and vehicles	22.1	25.8	30.4	29.6	30.6	29.7	(0.8)	-	-	-
Land	54.2	54.0	51.0	49.5	46.6	46.3	(0.3)	-	-	-
Other	30.9	29.0	23.2	21.6	20.3	21.1	0.8	-	-	-
Intangible assets	241.5	228.9	230.6	220.2	212.8	210.7	(2.0)	-	-	-
Goodwill	173.2	165.7	166.0	159.9	155.8	148.6	(7.2)	-	-	-
Sales rights	67.2	62.3	63.8	59.4	56.2	61.4	5.1	-	-	-
Other	1.0	0.8	0.8	0.7	0.7	0.6	(0.0)	-	-	-
Investments and other assets	42.5	46.0	46.9	30.6	36.4	35.6	(0.8)	-	-	-
Investment securities	22.7	27.6	28.4	116.0	14.0	12.5	(1.4)	-	-	-
Net defined benefit asset	6.4	5.8	6.1	6.5	6.9	7.5	0.6	-	-	-
Deferred tax assets	8.0	7.1	7.0	7.3	10.3	10.3	(0.0)	-	-	-
Other	5.2	5.3	5.2	5.0	5.1	5.2	0.0	-	-	-
Liabilities	113.7	100.0	97.5	96.0	105.9	97.0	(8.8)	-	-	-
Current liabilities	85.1	76.4	74.6	74.8	84.8	79.0	(5.7)	-	-	-
Notes and accounts payable-trade	22.7	24.5	17.2	16.3	19.0	23.2	4.2	-	-	-
Short-term loans payable	4.8	4.9	4.8	4.8	4.8	4.8	(0.0)	-	-	-
Accounts payable-other	39.2	29.9	35.4	30.8	39.8	33.3	(6.4)	-	-	-
Income taxes payable	7.7	4.4	8.7	10.3	11.8	4.5	(7.2)	-	-	-
Provision	2.7	5.5	2.0	6.3	2.7	5.7	2.9	-	-	-
Other	7.8	7.0	6.1	6.1	6.4	7.1	0.7	-	-	-
Non-current liabilities	28.5	23.5	22.9	21.2	21.0	17.9	(3.0)	-	-	-
Deferred tax liabilities	16.2	14.5	13.8	12.1	12.0	10.7	(1.3)	-	-	-
Net defined benefit liability	3.7	2.0	2.0	2.0	1.8	1.7	(0.1)	-	-	-
Provision	3.4	3.4	3.3	3.3	3.3	3.3	(0.0)	-	-	-
Other	5.1	3.5	3.6	3.6	3.7	2.1	(1.6)	-	-	-
Net assets	605.3	599.8	611.0	612.1	614.8	605.5	(9.2)	-	-	-
Shareholders' equity	580.4	576.8	581.7	591.3	594.9	595.5	0.5	-	-	-
Capital stock	26.7	26.7	26.7	26.7	26.7	26.7	-	-	-	-
Capital surplus	512.3	509.1	509.1	509.1	509.1	509.1	0.0	-	-	-
Retained earnings	68.1	67.6	72.5	82.2	85.9	86.5	0.5	-	-	-
Treasury shares	(26.6)	(26.6)	(26.7)	(26.8)	(26.8)	(26.8)	(0.0)	-	-	-
Accumulated other comprehensive income	24.5	22.6	28.9	20.4	19.4	9.5	(9.8)	-	-	-
Valuation difference on available-for-sale securities	2.7	5.1	5.0	2.2	2.9	2.1	(0.8)	-	-	-
Foreign currency translation adjustment	24.4	20.1	26.4	20.5	18.8	9.7	(9.1)	-	-	-
Remeasurements of defined benefit plans	(2.6)	(2.6)	(2.4)	(2.3)	(2.3)	(2.2)	0.1	-	-	-
Subscription rights to shares	0.3	0.3	0.3	0.3	0.4	0.4	0.0	-	-	-
Total liabilities and net assets	719.1	699.8	708.5	708.2	720.7	702.5	(18.1)	-	-	-

III. Operating Income or Loss by Segment

1. Pharmaceuticals segment

Billions of yen, rounded down

	FY 2015 results				FY 2016 results								FY 2016 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	68.0	135.3	208.7	279.2	68.0	(0.0)	100%	-	-	-	-	-	-	129.0	95%	268.0	96%
Japan	50.0	100.1	150.6	204.9	52.0	1.9	104%	-	-	-	-	-	-	95.2	95%	197.9	97%
International	17.9	35.1	58.1	74.3	15.9	(2.0)	89%	-	-	-	-	-	-	33.7	96%	70.0	94%
International sales ratio	26%	26%	28%	27%	23%	-	-	-	-	-	-	-	-	26%	-	26%	-
Americas	4.8	8.4	11.6	13.9	3.0	(1.8)	63%	-	-	-	-	-	-	4.9	58%	12.2	88%
Europe	8.9	18.1	33.4	42.4	8.8	(0.1)	98%	-	-	-	-	-	-	20.1	111%	39.9	94%
Asia	4.0	8.4	12.8	17.4	3.9	(0.0)	99%	-	-	-	-	-	-	8.4	101%	17.5	101%
Others	0.1	0.1	0.2	0.4	0.0	(0.0)	72%	-	-	-	-	-	-	0.1	64%	0.3	68%
Gross profit	45.0	93.9	148.2	196.4	44.2	(0.8)	98%	-	-	-	-	-	-	86.5	92%	186.4	95%
Selling, general and administrative expenses	37.2	75.3	113.2	160.2	38.3	1.0	103%	-	-	-	-	-	-	81.3	108%	163.4	102%
Operating income	7.7	18.5	34.9	36.2	5.9	(1.8)	76%	-	-	-	-	-	-	5.2	28%	23.0	64%

2. Bio-chemicals segment

	FY 2015 results				FY 2016 results								FY 2016 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	22.1	45.0	67.1	88.8	21.2	(0.9)	96%	-	-	-	-	-	-	43.0	96%	87.0	98%
Japan	12.1	24.1	36.7	48.9	11.8	(0.2)	98%	-	-	-	-	-	-	22.4	93%	46.3	95%
International	10.0	20.8	30.3	39.9	9.3	(0.6)	93%	-	-	-	-	-	-	20.6	99%	40.7	102%
International sales ratio	45%	46%	45%	45%	44%	-	-	-	-	-	-	-	-	48%	-	47%	-
Americas	2.5	5.2	7.9	10.2	2.8	0.3	113%	-	-	-	-	-	-	5.4	102%	10.8	106%
Europe	4.3	8.2	12.0	15.5	3.4	(0.8)	81%	-	-	-	-	-	-	8.1	98%	15.4	99%
Asia	3.0	7.0	9.8	13.6	2.9	(0.1)	96%	-	-	-	-	-	-	6.8	97%	14.0	103%
Others	0.1	0.3	0.4	0.5	0.1	(0.0)	71%	-	-	-	-	-	-	0.3	95%	0.5	84%
Gross profit	6.8	15.0	22.7	29.6	7.3	0.4	107%	-	-	-	-	-	-	15.0	99%	29.8	101%
Selling, general and administrative expenses	5.3	11.0	16.3	21.4	4.9	(0.3)	93%	-	-	-	-	-	-	11.2	101%	22.8	106%
Operating income	1.4	3.9	6.4	8.1	2.3	0.8	159%	-	-	-	-	-	-	3.8	95%	7.0	86%

IV. Operating Income or Loss of Main Pharmaceuticals Subsidiaries

(1) Kyowa Kirin International (GBP)¹

Millions of GBP, rounded down

	FY 2015 results				FY 2016 results								FY 2016 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	53.7	108.7	163.7	222.0	60.6	6.9	113%	-	-	-	-	-	-	111.9	103%	226.1	102%
Cancer pain Abstral	12.9	27.5	42.6	60.0	15.7	2.8	122%	-	-	-	-	-	-	29.8	109%	61.0	102%
Cancer pain PecFent	5.4	10.9	16.9	22.2	5.9	0.5	110%	-	-	-	-	-	-	13.7	125%	27.6	124%
Anticancer Mitomycin C	4.6	9.8	14.6	18.5	4.4	(0.2)	95%	-	-	-	-	-	-	8.2	84%	16.5	89%
Chemotherapy-induced nausea and vomiting drug Sancuso	3.9	8.2	12.7	17.2	3.8	(0.0)	98%	-	-	-	-	-	-	8.9	108%	19.1	111%
Replacement therapy with testosterone for male hypogonadism Tostran	5.8	9.2	12.2	17.5	4.7	(1.1)	80%	-	-	-	-	-	-	5.7	63%	10.8	62%
Relief of pain associated with chronic anal fissures Rectogesic	2.8	5.4	7.9	10.3	2.9	0.1	105%	-	-	-	-	-	-	4.9	90%	9.6	94%
Osteoporosis drug Adcal-D3	6.7	13.2	20.3	27.2	5.9	(0.7)	88%	-	-	-	-	-	-	12.6	95%	26.3	97%
Others	11.3	24.1	36.1	48.6	17.0	5.7	151%	-	-	-	-	-	-	27.7	115%	54.7	112%
Gross profit	38.9	81.4	121.2	163.2	47.7	8.8	123%	-	-	-	-	-	-	84.7	104%	166.9	102%
Selling, general and administrative expenses ²	20.8	42.0	61.6	88.1	22.4	1.6	108%	-	-	-	-	-	-	45.7	109%	89.4	101%
R&D expenses ²	1.6	3.0	5.0	6.8	4.5	2.9	277%	-	-	-	-	-	-	10.9	356%	21.0	307%
EBITDA ³	16.4	36.2	54.5	68.2	20.7	4.2	126%	-	-	-	-	-	-	28.1	78%	56.4	83%
Depreciation and amortization ²	15.4	30.6	46.4	61.9	15.8	0.4	103%	-	-	-	-	-	-	31.2	102%	62.5	101%
Operating income	1.0	5.6	8.1	6.2	4.8	3.7	456%	-	-	-	-	-	-	(3.1)	-	(6.0)	-

1. On February 22, 2016, ProStrakan Group plc's company name was changed to Kyowa Kirin International plc.
2. R&D expenses, and Depreciation and amortization are not included in Selling, general and administrative expenses.
3. EBITDA = Operating income + depreciation + amortization
4. Geographical breakdown of sales for January - March 2016 is as follows:

UK	Europe (excluding UK)	Americas	Other
28.2%	49.6%	20.9%	1.3%

(2) Kyowa Medex Co., Ltd.

Billions of yen, rounded down

	FY 2015 results				FY 2016 results								FY2016 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Net sales	2.5	5.5	8.5	11.7	2.6	0.1	106%	-	-	-	-	-	-	5.7	102%	12.1	103%
Japan	2.1	4.6	7.0	9.8	1.9	(0.1)	93%	-	-	-	-	-	-	4.7	102%	10.1	103%
International	0.4	0.9	1.5	1.9	0.7	0.2	168%	-	-	-	-	-	-	0.9	103%	2.0	103%
International sales ratio	16%	16%	18%	16%	27%	-	-	-	-	-	-	-	-	16%	-	17%	-
Gross profit	1.3	2.9	4.5	6.1	1.2	(0.0)	96%	-	-	-	-	-	-	2.9	97%	6.2	102%
Selling, general and administrative expenses	1.2	2.6	4.0	5.3	1.3	0.0	102%	-	-	-	-	-	-	2.8	110%	5.8	108%
Operating income	0.0	0.3	0.4	0.8	(0.0)	(0.0)	-	-	-	-	-	-	-	0.0	2%	0.4	62%

V. Kyowa Hakko Kirin Sales of Main Products

Accumulative

Billions of yen, rounded down

	FY 2015 results				FY 2016 results								FY2016 forecasts				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Change Amount	%	Jan - Jun	%	Jan - Sep	%	Jan - Dec	%	Jan - Jun	%	Jan - Dec	%
Kyowa Hakko Kirin total	53.8	105.9	163.6	217.9	53.2	(0.5)	99%	-	-	-	-	-	-	97.7	92%	200.4	92%
Indication / Product name																	
<i>ESA formulation</i> Nesp	12.3	27.0	42.0	57.5	13.3	1.0	109%	-	-	-	-	-	-	26.8	99%	54.6	95%
<i>ESA formulation</i> Espo	0.4	0.9	1.4	1.9	0.4	(0.0)	95%	-	-	-	-	-	-	0.7	79%	1.4	78%
<i>Secondary hyperparathyroidism</i> Regpara	3.9	8.5	13.2	18.2	4.3	0.4	110%	-	-	-	-	-	-	9.1	106%	18.9	104%
<i>Secondary hyperparathyroidism</i> Rocaltrol	1.0	2.4	3.7	5.1	1.1	0.0	101%	-	-	-	-	-	-	1.7	71%	3.3	65%
<i>Type-2 diabetes</i> Onglyza	0.8	2.0	3.2	4.8	1.2	0.4	150%	-	-	-	-	-	-	3.2	160%	6.9	145%
<i>Cardiovascular (Hypertension & angina pectoris)</i> Coniel	2.4	5.0	7.4	10.0	2.0	(0.3)	83%	-	-	-	-	-	-	3.8	76%	7.4	74%
<i>Sustained-duration G-CSF</i> G-Lasta	1.4	3.8	6.7	10.3	3.6	2.2	259%	-	-	-	-	-	-	6.9	181%	15.0	146%
<i>G-CSF</i> Gran	1.3	2.8	4.4	5.9	1.0	(0.3)	75%	-	-	-	-	-	-	1.7	60%	3.3	56%
<i>Transdermal persistent pain</i> Fentos	1.2	2.8	4.4	6.1	1.3	0.0	107%	-	-	-	-	-	-	3.0	108%	6.5	106%
<i>Anticancer</i> Poteligeo	0.4	1.0	1.4	1.9	0.4	(0.0)	98%	-	-	-	-	-	-	0.8	87%	1.9	97%
<i>Chronic idiopathic thrombocytopenic purpura</i> Romiplate	0.6	1.3	2.1	3.0	0.7	0.1	121%	-	-	-	-	-	-	1.4	107%	3.1	104%
<i>Antiallergenic</i> Allelock	7.8	12.4	16.8	22.1	6.8	(0.9)	88%	-	-	-	-	-	-	11.0	89%	18.1	82%
<i>Antiallergic eyedrops</i> Patanol	7.4	8.8	10.7	12.8	7.3	(0.1)	98%	-	-	-	-	-	-	9.2	105%	12.2	96%
<i>Inflammatory bowel disease</i> Asacol	1.3	2.9	4.5	6.1	1.2	(0.1)	86%	-	-	-	-	-	-	2.5	87%	4.9	81%
<i>Psoriasis vulgaris</i> Dovobet	0.9	2.1	3.3	4.7	1.2	0.3	138%	-	-	-	-	-	-	2.8	129%	5.4	114%
<i>Parkinson's disease</i> Nourias	0.9	2.2	3.6	5.3	1.4	0.4	151%	-	-	-	-	-	-	3.2	142%	6.9	130%
<i>Antiepileptic</i> Depakene	2.0	4.2	6.4	8.7	1.8	(0.2)	90%	-	-	-	-	-	-	3.9	92%	7.7	89%
<i>Gastrointestinal</i> Nauzelin	0.8	1.7	2.5	3.5	0.7	(0.0)	89%	-	-	-	-	-	-	1.4	86%	2.8	81%
Technology Out-Licensing	1.7	3.7	11.3	11.9	0.5	(1.1)	30%	-	-	-	-	-	-	2.0	54%	7.3	61%

V. Kyowa Hakko Kirin Sales of Main Products

Quarterly





Billions of yen, rounded down

	FY 2015 results				FY 2016 results								
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Change Amount	%	Apr - Jun	%	Jul - Sep	%	Oct - Dec	%
Kyowa Hakko Kirin total	53.8	52.1	57.6	54.3	53.2	(0.5)	99%	-	-	-	-	-	-
Indication / Product name													
<i>ESA formulation</i> Nesp	12.3	14.7	14.9	15.4	13.3	1.0	109%	-	-	-	-	-	-
<i>ESA formulation</i> Espo	0.4	0.5	0.5	0.4	0.4	(0.0)	95%	-	-	-	-	-	-
<i>Secondary hyperparathyroidism</i> Regpara	3.9	4.6	4.6	4.9	4.3	0.4	110%	-	-	-	-	-	-
<i>Secondary hyperparathyroidism</i> Rocaltrol	1.0	1.3	1.3	1.3	1.1	0.0	101%	-	-	-	-	-	-
<i>Type-2 diabetes</i> Onglyza	0.8	1.1	1.2	1.5	1.2	0.4	150%	-	-	-	-	-	-
<i>Cardiovascular (Hypertension & angina pectoris)</i> Coniel	2.4	2.6	2.4	2.5	2.0	(0.3)	83%	-	-	-	-	-	-
<i>Sustained-duration G-CSF</i> G-Lasta	1.4	2.4	2.8	3.6	3.6	2.2	259%	-	-	-	-	-	-
<i>G-CSF</i> Gran	1.3	1.5	1.5	1.4	1.0	(0.3)	75%	-	-	-	-	-	-
<i>Transdermal persistent pain</i> Fentos	1.2	1.5	1.5	1.7	1.3	0.0	107%	-	-	-	-	-	-
<i>Anticancer</i> Poteligeo	0.4	0.5	0.4	0.5	0.4	(0.0)	98%	-	-	-	-	-	-
<i>Chronic idiopathic thrombocytopenic purpura</i> Romiplate	0.6	0.7	0.8	0.8	0.7	0.1	121%	-	-	-	-	-	-
<i>Antiallergenic</i> Allelock	7.8	4.6	4.4	5.2	6.8	(0.9)	88%	-	-	-	-	-	-
<i>Antiallergic eyedrops</i> Patanol	7.4	1.3	1.9	2.0	7.3	(0.1)	98%	-	-	-	-	-	-
<i>Inflammatory bowel disease</i> Asacol	1.3	1.5	1.5	1.6	1.2	(0.1)	86%	-	-	-	-	-	-
<i>Psoriasis vulgaris</i> Dovobet	0.9	1.2	1.1	1.4	1.2	0.3	138%	-	-	-	-	-	-
<i>Parkinson's disease</i> Nouria	0.9	1.2	1.4	1.6	1.4	0.4	151%	-	-	-	-	-	-
<i>Antiepileptic</i> Depakene	2.0	2.2	2.1	2.2	1.8	(0.2)	90%	-	-	-	-	-	-
<i>Gastrointestinal</i> Nauzelin	0.8	0.8	0.7	1.0	0.7	(0.0)	89%	-	-	-	-	-	-
Technology Out-Licensing	1.7	2.0	7.6	0.6	0.5	(1.1)	30%	-	-	-	-	-	-












VI. R&D Pipeline



Filed • Approved  antibody  protein  small molecule

As of Apr.20, 2016

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	NDA in preparation in CN	Kirin-Amgen	
				Renal Anemia	Filed in ID		
Oncology		Granisetron Patch	5-HT ₃ Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Filed in MY	Licensed from Solasia Pharma	
Immunology /Allergy		©KHK4827 Brodalumab Injection	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Filed in JP	Kirin-Amgen	
Other		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	Filed in TH, MY	Kirin-Amgen	

Phase II, Phase III








Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in Patients with Type 2 Diabetes	Phase II in JP	Licensed from Reata	
		©KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Phase III in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		©ARQ 197 Tivantinib Oral	c-Met Inhibitor	Hepatocellular Cancer	Phase III in JP	Licensed from ArQule	
		©BIW-8962 Injection	Anti-GM2 Humanized Antibody	Cancer	Phase I / II a in KR	In-House	POTELLIGENT®
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma Cutaneous T-cell Lymphoma	Phase II in US, EU and others Phase III in US, EU, JP and others	In-House	POTELLIGENT®
Immunology /Allergy		©KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma Chronic Obstructive Pulmonary Disease (COPD)	Phase III in JP and KR Phase III in JP	In-House	POTELLIGENT® Jointly Developed with AstraZeneca/MedImmune in JP and KR
		©ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Organ Transplant Rejection	Phase I in JP Phase II in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas
		Z-206 Mesalazine Oral	pH Dependent Controlled Release Tablet	Ulcerative Colitis (new dose regimen)	Phase III in JP	Licensed from Zeria Pharma	Jointly Developed with Zeria Pharma
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Phase III in US, CA, EU and others	In-House	
Other		©KRN23 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in adult patients	Phase III in US, CA, EU, JP and KR	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				X-linked Hypophosphatemia (XLH) in pediatric patients	Phase II in US and EU		
				Tumor Induced Osteomalacia (TIO)/Epidermal Nevus Syndrome (ENS)	Phase II in US		
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia	Phase II in KR	Kirin-Amgen	
				Idiopathic (Immune) Thrombocytopenic Purpura	Phase III in CN		


 Updated since Jan 22, 2016 (Area, Stage, Filed, Approved, etc.)
 New Molecular Entity

VI. R&D Pipeline

Ph I  antibody  protein  small molecule


As of Apr. 20, 2016

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KRN951 Tivozanib Oral	VEGF Receptor Inhibitor	Cancer	Phase I in JP	In-House	Being Developed Overseas by AVEO as AV-951
		©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	Phase I in JP	Syndax	
		©KHK2823 Injection	Anti-CD123 Fully Human Antibody	Cancer	Phase I in UK	In-House	POTELLIGENT® Human Antibody-Producing Technology
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I in US	In-House	POTELLIGENT® Combination with Durvalumab/Tremelimumab (Jointly Developed with AstraZeneca)
	Phase I / II in US				Combination with Docetaxel		
Phase I in JP	Combination with PF-05082566 (Jointly Developed with Pfizer)						
Immunology /Allergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Autoimmune diseases	Phase I in CA	In-House	POTELLIGENT® Human Antibody-Producing Technology
Central Nervous System		©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU	Licensed from Immunas Pharma	
					Phase I in JP		
Others		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase I in EU	In-House	


 Updated since Jan 22, 2016 (Area, Stage, Filed, Approved, etc.)
 © New Molecular Entity

Updated since Jan 22, 2016 (Area, Stage, Filed, Approved, etc.)


Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	NDA in preparation in CN	Kirin-Amgen	
				Renal Anemia	Filed in ID		

Ph I

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I / II in US	In-House	POTELLIGENT® Combination with Nivolumab (Jointly Developed with Bristol-Myers Squibb)

Terminated

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KHK2898 Injection	Anti-CD98 Fully Human Antibody	Cancer	Phase I in SG	In-House	POTELLIGENT® Human Antibody-Producing Technology

<Appendix> Pipeline of Biosimilar

Phase III

As of Jan. 22, 2016

Code Name	Generic Name	Stage	Remarks
FKB327	Adalimumab (fully human anti-TNF- α monoclonal antibody)	Phase III in US and others	Fujifilm Kyowa Kirin Biologics

Phase I

Code Name	Generic Name	Stage	Remarks
FKB238	Bevacizumab (humanized anti-VEGF monoclonal antibody)	Phase I in UK	Centus Biotherapeutics